CAR-T immunotherapy: how will it change treatment for acute lymphoblastic leukemia and beyond?

Christian M. Capitini

Open source

DOI
10.1080/21678707.2018.1529562
Published
2018-10-03
Container
Expert Opinion on Orphan Drugs
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/21678707.2018.1529562,
  title = {CAR-T immunotherapy: how will it change treatment for acute lymphoblastic leukemia and beyond?},
  author = {Christian M. Capitini},
  year = {2018},
  journal = {Expert Opinion on Orphan Drugs},
  doi = {10.1080/21678707.2018.1529562},
  url = {https://doi.org/10.1080/21678707.2018.1529562}
}

RIS

TY  - JOUR
TI  - CAR-T immunotherapy: how will it change treatment for acute lymphoblastic leukemia and beyond?
AU  - Christian M. Capitini
PY  - 2018
JO  - Expert Opinion on Orphan Drugs
DO  - 10.1080/21678707.2018.1529562
UR  - https://doi.org/10.1080/21678707.2018.1529562
ER  - 

APA

Capitini, C. M. (2018). CAR-T immunotherapy: how will it change treatment for acute lymphoblastic leukemia and beyond?. Expert Opinion on Orphan Drugs. https://doi.org/10.1080/21678707.2018.1529562

Source records